Evidence map›Paper›PMID 28629476›Full record

ArticleJournal of translational medicine2017

Stromal vascular fraction cells for the treatment of critical limb ischemia: a pilot study.

Adas Darinskas, Mindaugas Paskevicius, Gintaras Apanavicius, Gintaris Vilkevicius, Liutauras Labanauskas, Thomas E Ichim, Rytis Rimdeika

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Adas DarinskasLaboratory of Immunology, National Cancer Institute, Santariskiu Str. 1, 08660, Vilnius, Lithuania. darinskas.adas@gmail.com.ORCID http://orcid.org/0000-0002-1916-7535
Mindaugas PaskeviciusDepartment of Vascular Surgery, Vilnius City Clinical Hospital, Antakalnio Str. 57, 10207, Vilnius, Lithuania.
Gintaras ApanaviciusDepartment of Vascular Surgery, Vilnius City Clinical Hospital, Antakalnio Str. 57, 10207, Vilnius, Lithuania.
Gintaris VilkeviciusNorthway Medical and Surgical Center, S.Zukausko Str. 19, 08234, Vilnius, Lithuania.
Liutauras LabanauskasDepartment of Plastic and Reconstructive Surgery, Lithuanian University of Health Sciences, Medical Academy, University Clinics of Kaunas, Eiveniu Str. 2, 50009, Kaunas, Lithuania.
Thomas E IchimImmune Advisors LLC, San Diego, CA, 92121, USA.
Rytis RimdeikaDepartment of Plastic and Reconstructive Surgery, Lithuanian University of Health Sciences, Medical Academy, University Clinics of Kaunas, Eiveniu Str. 2, 50009, Kaunas, Lithuania.
Vilnius University · LTLithuanian University of Health Sciences · LTHealthcentric Advisors · USNational Cancer Institute · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCell-based therapy is being explored as an alternative treatment option for critical limb ischemia (CLI), a disease associated with high amputation and mortality rates and poor quality of life. However, therapeutic potential of uncultured adipose-derived stromal vascular fraction (SVF) cells has not been evaluated as a possible treatment. In this pilot study, we investigated the efficacy of multiple injections of autologous uncultured adipose-derived SVF cells to treat patients with CLI.

methodsThis study included 15 patients, from 35 to 77 years old, with rest pain and ulceration. SVF cells were injected once or twice in the ischemic limb along the arteries. Digital subtraction angiography was performed before and after cell therapy. The clinical follow up was carried out for the subsequent 12 months after the beginning of the treatment.

resultsMultiple intramuscular SVF cell injections caused no complications during the follow-up period. Clinical improvement occurred in 86.7% of patients. Two patients required major amputation, and the amputation sites healed completely. The rest of patients achieved a complete ulcer healing, pain relief, improved ankle-brachial pressure index and claudication walking distance, and had ameliorated their quality of life. Digital subtraction angiography performed before and after SVF cell therapy showed formation of numerous vascular collateral networks across affected arteries.

conclusionResults of this pilot study demonstrate that the multiple intramuscular SVF cell injections stimulate regeneration of injured tissue and are effective alternative to achieve therapeutic angiogenesis in CLI patients who are not eligible for conventional treatment. Trial registration number at ISRCTN registry, ISRCTN13001382. Retrospectively registered at 26/04/2017.

Indexed as

AdultAgedFemaleHumansIschemiaLower ExtremityMaleMiddle AgedPilot ProjectsStromal CellsUpper ExtremityWound HealingAngiogenesisArteriosclerosis obliteransCritical limb ischemiaStromal vascular fraction cells

Identifiers

PMID28629476
PMCPMC5477131
OpenAlexW2672586601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.